Our data suggest that serum IL-10 levels increase with tumor progression, whereas the level of TGF-β initially indicates that it inhibits epithelial growth, and the latter (day 40) appears to promote tumor progression (Figure 1I). The gene discussed is TGFB1; the disease is neoplasm.